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Articles
Estimates of possible severe bacterial infection in neonates 
in sub-Saharan Africa, south Asia, and Latin America for 
2012: a systematic review  and meta-analysis
Anna C Seale, Hannah Blencowe, Alexander A Manu, Harish Nair, Rajiv Bahl, Shamim A Qazi, Anita K Zaidi, James A Berkley, Simon N Cousens, 
Joy E Lawn, for the pSBI Investigator Group*
Summary
Background Bacterial infections are a leading cause of the 2·9 million annual neonatal deaths. Treatment is usually 
based on clinical diagnosis of possible severe bacterial infection (pSBI). To guide programme planning, we have 
undertaken the ﬁ rst estimates of neonatal pSBI, by sex and by region, for sub-Saharan Africa, south Asia, and Latin 
America.
Methods We included data for pSBI incidence in neonates of 32 weeks’ gestation or more (or birthweight ≥1500 g) with 
livebirth denominator data, undertaking a systematic review and forming an investigator group to obtain unpublished 
data. We calculated pooled risk estimates for neonatal pSBI and case fatality risk, by sex and by region. We then applied 
these risk estimates to estimates of livebirths in sub-Saharan Africa, south Asia, and Latin America to estimate cases and 
associated deaths in 2012.
Findings We included data from 22 studies, for 259 944 neonates and 20 196 pSBI cases, with most of the data (18 of 
the 22 studies) coming from the investigator group. The pooled estimate of pSBI incidence risk was 7·6% 
(95% CI 6·1–9·2%) and the case-fatality risk associated with pSBI was 9·8% (7·4–12·2). We estimated that in 2012 
there were 6·9 million cases (uncertainty range 5·5 million–8·3 million) of pSBI in neonates needing treatment: 
3·5 million (2·8 million–4·2 million) in south Asia, 2·6 million (2·1 million–3·1 million) in sub-Saharan Africa, and 
0·8 million (0·7 million–1·0 million) in Latin America. The risk of pSBI was greater in boys (risk ratio 1·12, 95% CI 
1·06–1·18) than girls. We estimated that there were 0·68 million (0·46 million–0·92 million) neonatal deaths 
associated with pSBI in 2012. 
Interpretation The need-to-treat population for pSBI in these three regions is high, with ten cases of pSBI diagnosed 
for each associated neonatal death. Deaths and disability can be reduced through improved prevention, detection, and 
case management.
Funding The Wellcome Trust and the Bill & Melinda Gates Foundation through grants to Child Health Epidemiology 
Reference Group (CHERG) and Save the Children’s Saving Newborn Lives programme.
Copyright © Seale et al. Open Access article distributed under the terms of CC BY. 
Introduction
Severe bacterial infection in neonates, including sepsis, 
meningitis, and pneumonia, is an important contributor 
to the global burden of disease, accounting for about 3% of 
all disability-adjusted life years—a similar burden to that 
of HIV/AIDS.1,2 Most of these disability-adjusted life years 
are attributable to deaths, because infections are a leading 
cause of the 2·9 million global neonatal deaths.3,4 However, 
in addition to substantial immediate mortality, survivors of 
severe bacterial infection in the neonatal period (ﬁ rst 
28 days of life) are at risk of long-term disability.5 Timely 
detection and appropriate case management could save 
hundreds of thousands of newborn lives.6 But, by contrast 
with HIV,7 childhood pneumonia,8 and malaria,9 no 
published estimates of the incidence of severe neonatal 
bacterial infection are available. This information is 
essential to guide health-programme priorities and policy 
in support of the post-2015 agenda to end preventable child 
deaths. It aligns closely with WHO’s Every Newborn 
Action Plan,10 which sets a target of ten or fewer neonatal 
deaths per 1000 livebirths in every country by 2035.11
The clinical diagnosis of severe neonatal bacterial 
infection is challenging, recognition of illness by a baby’s 
primary caregiver can occur late, symptoms can be subtle 
and proceed rapidly, and signs can be non-speciﬁ c and 
diﬃ  cult to detect. In resource-poor settings, ﬁ rst-line care is 
rarely given by those with specialist paediatric training, and 
reliable microbiological investigations to support diagnoses 
are uncommon outside of research centres. Clinical 
algorithms have been developed to direct treatment of 
neonates identiﬁ ed with possible severe bacterial infection 
(pSBI) as in the WHO guidelines of the Integrated 
Management of Childhood Illness.12 This algorithm was 
initially informed by the ﬁ rst WHO Young Infants Study in 
the 1990s,13 which identiﬁ ed 14 clinical signs and symptoms 
predictive of severe bacterial disease. However, these 
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See Online for appendix
guidelines excluded neonates in the ﬁ rst week of life, when 
the risk of infection and death are highest but clinical 
signs are less speciﬁ c compared with older children. The 
subsequent WHO Young Infants Clinical Signs Study 
(YICSS),12 focused on clinical signs detected by primary 
care health workers for 3177 neonates in the ﬁ rst week of 
life attending health-care facilities in countries within sub-
Saharan Africa, south Asia, and Latin America: Bangladesh, 
Bolivia,14 Ghana,15 India,16 Pakistan, and South Africa.17 The 
presence of any one of seven clinical signs and symptoms 
predicted severe bacterial illness (on the basis of an 
experienced paediatrician’s assessment) with a sensitivity 
of 85% and speciﬁ city of 75%, in those seeking care.12 Due 
to the likely high mortality in neonates with severe bacterial 
infection who are not treated, clinical algorithms to 
diagnose pSBI prioritise sensitivity over speciﬁ city, so this 
diagnosis includes other disorders such as transient 
tachypnoea, hypoglycaemia, respiratory distress associated 
with preterm birth, birth asphyxia, and viral respiratory 
infections (ﬁ gure 1).18
In both resource-poor and resource-rich settings, 
challenges exist in the diagnosis of severe neonatal bacterial 
infection. However, in rich countries, diagnosis is usually 
done by experienced paediatricians, and almost all cases of 
pSBI are investigated with a full sepsis screen (testing of 
blood, cerebrospinal ﬂ uid, and urine for signs of infection) 
and by haematological and biochemical investigations. 
Clinical algorithms are also used in resource-rich regions, 
but focus on the prediction of outcomes in very high-risk 
neonates; for example, the clinical risk index for babies, 
which assesses likelihood of hospital death in preterm 
neonates on the basis of gestational age, birthweight, 
maximum and minimum fraction of inspired oxygen, 
maximum base excess during the ﬁ rst 12 h, and presence 
of congenital malformations.19 Despite the additional 
expertise and investigations available in resource-rich 
settings, diﬀ erentiation of bacterial illness from other 
disorders is diﬃ  cult, and the improvement of diagnoses, 
for example through the use of novel markers of infection, 
is an important area of research.20
Estimation of the burden of pSBI is important to plan 
for health systems’ response, in terms of staﬀ , 
commodities, and, when required, inpatient care. There 
is variation in reported incidence of neonatal pSBI, which 
might be aﬀ ected by diﬀ erences in diagnostic criteria and 
case-ﬁ nding strategies, as well as by true diﬀ erences 
between populations.21 In studies from India,22,23 
Bangladesh,24–26 Pakistan,27 and Nepal,28,29 pSBI incidence 
risks range from 50 cases to 217 cases per 1000 livebirths.
We aimed to estimate the burden of pSBI in neonates 
(excluding very preterm neonates, <32 weeks gestation 
or <1500 g birthweight) and associated mortality, in south 
Asia, sub-Saharan Africa, and Latin America in 2012. To 
do this we calculated pooled estimates of incidence risk 
and case-fatality risk for pSBI in neonates, by sex, by 
doing meta-analyses after a systematic review of 
published and unpublished data.
Methods
Search strategy and selection criteria
We searched PubMed and WHO regional databases 
(AFRO, EMRO, Lilacs) to identify published data for 
incidence of pSBI (ﬁ gure 2). We applied no language or 
date restrictions. Search terms included multiple variants 
of terms covering the areas “newborn/infant” and 
“infection” and we used Medical Subject Headings terms 
when available (see appendix for full details). We used 
snowball searching to identify further studies by 
screening the reference lists of retrieved studies. We did 
our last search on April 7, 2014.
We deﬁ ned pSBI according to the YICSS criteria as the 
presence of any one of a history of diﬃ  culty feeding, 
history of convulsions, movement only when stimulated, 
respiratory rate of 60 or more breaths per min, severe 
chest indrawing, and a temperature of 37·5°C or higher 
or 35·5°C or lower.12 The details of the clinical signs and 
symptoms used for diagnosis in each included study are 
shown in the appendix.
Sub-Saharan Africa included Global Burden of Disease 
(GBD) sub-Saharan Africa regions central, east, west, 
and southern. South Asia included GBD regions south 
Asia and southeast Asia. Latin America included GBD 
regions central, Andean, southern, and tropical Latin 
America and the Caribbean.31
We searched for ongoing or recently completed 
unpublished clinical trials on ClinicalTrials.gov, and 
contacted Health and Demographic Surveillance 
Systems, and relevant research networks such as the 
Healthy Newborn Network and the Oxford tropical 
network. We also contacted funding agencies or their 
overseas centres (the Bill & Melinda Gates Foundation, 
Saving Newborn Lives, WHO, the Joint United Nations 
Programme on HIV/AIDS, the Wellcome Trust, and the 
Medical Research Council) to request data from studies 
meeting our inclusion criteria. We also contacted 
members of the investigator group contributing data to a 
study of the global burden of lower respiratory tract 
For Health and Demographic 
Surveillance Systems see http://
www.indepth-network.org/
For the Healthy Newborn 
Network see http://www.
healthynewbornnetwork.org/
For the Oxford tropical network 
see http://www.
tropicalmedicine.ox.ac.uk/home
Viruses
Tetanus
Urinary tract
infection
Diarrhoea
Skin infections
Congenital
heart disease
Respiratory
disorders
Congenital
infections
Birth asphyxia
(and other
intrapartum
related
conditions)Pneumonia
Meningitis Sepsis
Possible severe bacterial infection
Figure 1: Possible severe bacterial infection (pSBI) and overlap with other 
clinical syndromes
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infections.8 We subsequently assembled the pSBI 
Investigator Group to include secondary analyses of data 
from published and as yet unpublished studies. Investi-
gators were asked to reanalyse data using a common data 
template and analytic framework, when appropriate, and 
to join the pSBI Investigator Group.
To be included in our analysis, studies had to meet all 
inclusion criteria: they had to be recent (data obtained no 
earlier than 1998), a denominator for the population at 
risk had to be available, and diagnosis of pSBI had to be 
established on the basis of the presence of speciﬁ ed signs 
and symptoms. We excluded studies of preterm babies 
(<32 weeks gestation) and very low birthweight babies 
(<1500 g), and where possible excluded data for these 
neonates from secondary analyses, because death and 
disability in very preterm newborns is more a 
consequence of their prematurity than infection alone.
We did not exclude studies on the basis of their method 
of case ascertainment, but categorised them as active 
prospective case ﬁ nding (community workers visit 
homes and assess neonates according to a schedule), 
active retrospective case ﬁ nding (community workers 
visit homes and ask about signs and symptoms that 
occurred in the neonatal period), or passive case ﬁ nding 
(recording attendance at a health centre). We categorised 
studies as such to allow assessment of the eﬀ ect of 
diﬀ erent methods of case ascertainment on estimates of 
pSBI incidence risk, because studies with active 
follow-up would include neonates who might not have 
otherwise sought care, or might have died at home, by 
contrast with passive case ﬁ nding, in which such cases 
would be missed. To further assess the eﬀ ect of diﬀ ering 
methods of case ascertainment, we categorised the 
frequency of visits in active, prospective case-ﬁ nding 
studies into frequent visits (four or more visits during 
the neonatal period) or less-frequent visits (fewer than 
four visits during the neonatal period). We also 
diﬀ erentiated between studies that included inter-
ventions and those that did not.
When possible, we re-analysed data to deﬁ ne pSBI 
cases according to the YICSS algorithm, but because this 
was not always possible, we categorised studies into 
those using the YICSS algorithm exactly, those using a 
modiﬁ ed YICSS algorithm, and those using substantially 
diﬀ erent criteria (see appendix for details).
Datasets analysed by the original study investigators 
were approved under the existing site’s institutional 
review board. Further ethical review was not applicable 
for secondary data analysis of aggregated data from the 
pSBI investigator group.
Statistical analysis
We calculated pooled estimates using random eﬀ ects 
models (Der-Simoninan and Laird method).32 We used 
random eﬀ ects models because they allow for hetero-
geneity across studies by use of a statistical parameter 
representing the variation between studies. We expected 
heterogeneity because of true diﬀ erences in the pSBI 
incidence and associated mortality in study sites within 
the regions studied. These diﬀ erences would be expected 
due to diﬀ ering socioeconomic conditions, population 
comorbidities, and environments; some studies were 
done in predominantly urban areas, others were done in 
rural areas. Similarly, study design variations might have 
introduced heterogeneity. We assessed the extent to 
which results varied across studies using the I² statistic, 
which estimates the proportion of variability between 
studies due to actual diﬀ erences in results versus chance 
diﬀ erences, with higher values suggesting more hetero-
geneity.33
We estimated incidence risk and case-fatality risk of 
pSBI overall, by region, and by sex. We further investi-
gated the eﬀ ect of sex by calculating a pooled estimate for 
the risk ratio for pSBI in both sexes. We used this pooled 
risk ratio to derive the incidence risk in both sexes from 
the overall incidence risk of pSBI, because not all the 
studies included data for sex.
We assessed the eﬀ ect of case ascertainment method, 
frequency of home visits, diagnostic algorithm used, and 
whether or not there was an intervention, by calculating 
separate pooled estimates of pSBI incidence risk, looking 
at estimates within categories for each of these factors. 
We then did a sensitivity analysis, calculating a second 
pooled estimate of pSBI incidence risk, but including 
only those studies with active, prospective case ascertain-
ment and using the YICSS algorithm (exact or modiﬁ ed) 
for diagnosis of pSBI.
We used a standard compartmental model,2 applying 
our pooled overall estimate of pSBI incidence risk to 
estimates of the number of livebirths (not including 
babies of <32 weeks gestation or <1500 g birthweight),34 
by region and by sex in 2012.35 We applied pSBI incidence 
1949 records excluded (did not meet eligibility criteria)
2 articles excluded (more recent data available from the 
    same population and site)
22 full-text articles assessed for eligibility
1955 records identified through databases 
            searches and screened
22 studies re-analysed and included in 
      quantitative synthesis (meta-analysis)
18 additional records identified
      through other sources (eg, trials,
      funders, health networks, and other
      investigator groups)
6 studies identified
Figure 2: Data search and extraction30
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risks for both sexes (derived from the risk ratio as 
described above) to estimates of livebirths by region and 
by sex.35 We then applied the overall case-fatality risk to 
cases of pSBI, to provide an estimate of deaths after 
pSBI.
We derived a quantitative assessment of the uncertainty 
in the estimate of pSBI cases, and in consequent 
estimates of pSBI deaths, by taking 1000 random draws, 
assuming a normal distribution with a mean equal to the 
point estimate of the parameter and SD equal to the 
estimated SE of the parameter. This allowed for 
uncertainty in the number of cases to be captured in the 
estimation of the number of deaths. We calculated the 
2·5th and 97·5th centiles of the resulting distributions as 
the uncertainty range.
We used Stata (version 12) for all statistical analyses. 
Role of the funding source
The study sponsors had no role in the study design, or in 
the collection, analysis, and interpretation of data, or in 
the writing of the report. ACS had full access to all the 
data in the study, and ACS, JEL, and HB had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Our systematic review identiﬁ ed 1955 abstracts (ﬁ gure 2), 
from which we identiﬁ ed six eligible studies24–28,36 meeting 
our inclusion criteria. We excluded two otherwise eligible 
studies24,25 because more recent data were available from 
the same study site. We included data from an additional 
18 studies identiﬁ ed from other sources (ﬁ gure 3).37
We included 22 studies in the initial analysis (ﬁ gure 2, 
table 1). The total study population included 259 944 neo -
nates, with 20 196 cases of pSBI. 15 studies used active 
prospective case ﬁ nding,27,37, 38 40–48 six studies used active 
retrospective case ﬁ nding,39 and one study used passive 
case ﬁ nding (unpublished). Eight studies used the 
YICSS algorithm exactly,42,45,46 eleven used modiﬁ ed 
YICSS criteria (eg, inclusion of omphalitis),27,37,39–41,43,47,48 
and three studies used criteria with important 
diﬀ erences from the YICSS algorithm—these were the 
studies from the Thai–Myanmar border,44 India 
(Ballabgarh, Haryana state),38 and Peru (unpublished; 
see the appendix for details of study algorithms).
The pooled estimate of pSBI incidence risk including 
all 22 studies was 7·6% (95% CI 6·1–9·2%; ﬁ gure 4). We 
saw no evidence that estimated pSBI risk was higher in 
studies with prospective com munity follow-up than with 
retrospective community follow-up (see the appendix for 
this meta-analysis), and only one study used passive 
follow-up (facility-based). Among studies with prospective 
follow-up and four or more visits in the neonatal period, 
the estimated incidence risk of pSBI was 8·3% (5·5–11·1), 
and for those with fewer than four visits the incidence 
risk of pSBI was 6·3% (3·9–8·6). Studies including 
interventions did not have a lower incidence risk of pSBI 
(appendix). In terms of the algorithm used, the incidence 
risk reported in studies using the YICSS algorithm exactly 
was 8·2% (4·9–11·5) versus 8·1% (6·1–10·1) in those 
with a modiﬁ ed version and 4·3% (1·1–7·5) in those 
using sub stantially diﬀ erent criteria (appendix). When 
restricting the analysis to the 12 studies with active follow 
up and using the YICSS algorithm for diagnosis 
(sensitivity analysis), the pooled estimate for pSBI 
incidence risk was 8·4% (6·0–10·7; appendix).
Incidence risks by region are presented in table 2. 
Although the overall incidence risk of pSBI was within 
the 95% conﬁ dence limits for each region, we saw a 
higher point estimate of incidence in Latin America than 
south Asia and sub-Saharan Africa (table 2). We saw 
much heterogeneity between results of studies within 
regions (I²≥95%; ﬁ gure 4).
Overall, case-fatality risk associated with pSBI was 
9·8% (95% CI 7·4–12·2; shown in table 2 by region; see 
Figure 3: Geographical distribution of the 22 included studies
The number of studies per country is shown in parentheses after country name.
Sub-Saharan Africa
South Asia
Latin America
Active (prospective)
Active (retrospective)
Passive (facility-based)
Guatemala (two)
Peru (one)
Argentina (one)
Ghana (one)
Zambia (three)
Kenya (two)
Indonesia (one)
Thai–Myanmar border (one)
Pakistan (three)
Bangladesh (one)
India (three)
Nepal (three)
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appendix for the meta-analysis). Case-fatality risk 
estimates were higher in three studies,39 all with 
retrospective case-ﬁ nding (ﬁ gure 5), and again we saw 
much heterogeneity between studies, especially within 
south Asia and sub-Saharan Africa (I²≥97·8% for south 
Asia and sub-Saharan Africa; I²=43·7% for Latin 
America).
Boys had a higher risk of pSBI than did girls (data from 
18 study sites): the risk ratio for pSBI in boys versus 
girls was 1·12 (1·06–1·18, see appendix for meta-
analysis). All regions had increased risk in boys 
compared with girls, with this eﬀ ect was most 
pronounced in Latin America (risk ratio 1·23, 
95% CI 1·10–1·37) and little evidence of heterogeneity 
Country Location Rural or 
mixed 
(rural-
urban)
Intervention Neonatal 
mortality 
rate per 
1000 
livebirths
Year
(median)
Period of 
data 
collection
Algorithm* Case ascertainment
Mitra et al 
(unpublished)
Bangladesh Sylhet Rural Cord cleansing with 
chlorhexidine
28·3 2008 2007–09 YICSS Visit on days 1, 3, 6, 9, and 15 
Broor et al38 India Ballabgarh,
Haryana State 
Rural None 37 2003 2001–04 Danger sign or fast breathing, 
indrawing, nasal ﬂ aring, or 
grunting
Visit on day 7
MNHR39 India Nagpur District Mixed None (health registry) 26·2 2012 2012 YICSS adapted Visit on day 1 or 2 and on day 42
MNHR39 India Belgaum district Mixed None (health registry) 26·2 2012 2012 YICSS adapted Visit on day 1 or 2 and on day 42
Khanal et al40 Nepal Morang District Rural Community care 33 2006 2005–07 YICSS adapted; included skin 
and umbilicus infection
Visit on days 1 and 60 
Saville et al37 Nepal Dhanusha Rural Community 
interventions
32·5 2009 2007–11 YICSS adapted to include 
umbilical and skin infection
Visit on days 1, 3, 14, and 28
Mullany et al36,41 Nepal Sarlahi District Rural Chlorhexidine skin and 
umbilicus cleansing
32·1 2004 2002–06 YICSS; any two criteria Visit on days 1, 2, 3, 4, 6, 8, 10, 
12, 14, 21, and 28
Zaidi et al27 Pakistan Karachi Mixed Outpatient 
management of 
infection
45 2005 2003–08 YICSS adapted Visit days 1, 3, 6, 15, and 30
Bhutta et al42 Pakistan Matiari Rural None 51 2012 2011–12 YICSS Visit on days 1, 3, 6, 9, and 15 
Sooﬁ  et al 
(unpublished) 
Pakistan District 
Naushero Feroze
Rural None 44 2011 2010–12 YICSS Visit on days 1, 3, 6, 9, and 15
Simoes et al43 Indonesia West Java 
District
Mixed None NA 1999 1998–2001 YICSS adapted (excluding 
convulsions, poor feeding)
Visit on days 7, 14, 21, and 28
Turner et al44 Thai–Myanmar 
border
Thai–Myanmar 
border
Rural None 15·9 2009 2009–10 Fever or two signs of severe 
disease
Visit on days 7 and 28
Kirkwood et al45 Ghana Brong-Ahafo 
region
Rural Community care 32·3 2009 2008–09 YICSS Three visits in ﬁ rst 7 days of life 
Berkley et al 
(unpublished)
Kenya Kiliﬁ  District Rural None 13·3 2010 2009–11 YICSS Neonates admitted to district 
hospital
MNHR39 Kenya Western 
Highlands
Rural None (health registry) 15·5 2012 2012 YICSS adapted Visit on day 1 or 2 and on day 42
Hamer et al 
(unpublished)
Zambia Southern 
Province
Rural Cord cleansing with 
chlorhexidine
14·9 2012 2011–13 YICSS adapted; including 
jaundice and umbilicus 
infection
Visits on day 1, 4, 10, and 28 
MNHR39 Zambia Chongwe and 
Kafue District
Mixed None (health registry) 22·7 2012 2012 YICSS adapted Visit on day 1 or 2 and on day 42
Gill et al46 Zambia Lufwanyama 
District
Rural Community care 30·4 2007 2006–08 YICSS At routine contact for 
postpartum visits
MNHR39 Argentina Corrientes and 
Santiago 
Districts
Rural None (health registry) 8·2 2012 2012 YICSS adapted Visit on days 1 or 2 and on 
day 42
MNHR39 Guatemala Chimaltenango 
District
Mixed None (health registry) 25·2 2012 2012 YICSS adapted Visit on day 1 or 2 and on day 42
Bruce et al47,48 Guatemala Highlands Rural Reducing indoor air 
pollution
N/A 2008 2002–04 YICSS (except indrawing) Visit days 7, 14, 21, and 28
Tinoco et al 
(unpublished)
Peru Lima, Tumbes, 
Cuzco, Puerto 
Maldonado
Mixed None 9 2010 2009–11 Inﬂ uenza-like illness Visit three times per week
MNHR=Maternal and Newborn Health Registry. NA=not applicable. YICSS=Young Infants Clinical Signs Study. *See appendix for further information.
 Table 1: Overview of the 22 included studies of possible severe bacterial infection
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between the three study sites included.39,47,48 We saw no 
evidence for a diﬀ erence in case-fatality risk between 
boys and girls with pSBI (1·06; 0·91–1·24; see appendix 
for meta-analysis).
Estimates of burden of disease were based on number of 
livebirths of 32 weeks gestation or more (or ≥1500 g 
birthweight) by country and sex in 2012 and by applying 
overall incidence risk of pSBI. We did not apply region-
South Asia
Mitra et al(unpublished)
Broor et al38
MNHR39
MNHR39
Khanal et al40
Saville et al37
Mullany et al41 
Zaidi et al27
Bhutta et al42
Soofi et al(unpublished)
Simoes et al43
Turner et al44
Subtotal (I2=99·6%; p=0·000)
Sub-Saharan Africa
Kirkwood et al45
Berkley et al(unpublished) 
MNHR39
Hamer et al(unpublished)
MNHR39
Gill et al46
Subtotal (I2=99·5%; p=0·000)
Latin America
MNHR39
MNHR39
Bruce et al47,48
Tinoco et al(unpublished)
Subtotal (I2=96·3%; p<0·0001)
 
Overall (I2=99·6%; p<0·0001)
Country
Bangladesh
India
India
India
Nepal
Nepal
Nepal
Pakistan
Pakistan
Pakistan
Indonesia
Thai–Myanmar border
Ghana
Kenya
Kenya
Zambia
Zambia
Zambia
Argentina
Guatemala
Guatemala
Peru
Denominator
30 994
281
9205
20 506
11 457
11 177
23 662
36 687
10 185
13 784
940
553
16 168
24 989
7954
21 815
6329
3497
2903
6377
211
270
Cases (n)
4468
5
474
1148
1051
525
1954
2727
1073
1561
3
38
832
858
1227
617
172
283
265
853
50
12
Eﬀect Size (95% CI)
0·14 (0·14–0·15)
0·02 (0·01–0·04)
0·05 (0·05–0·06)
0·06 (0·05–0·06)
0·09 (0·09–0·10)
0·05 (0·04–0·05)
0·08 (0·08–0·09)
0·07 (0·07–0·08)
0·11 (0·10–0·11)
0·11 (0·11–0·12)
0·00 (0·00–0·01)
0·07 (0·05–0·09)
0·07 (0·05–0·09)
0·05 (0·05–0·05)
0·03 (0·03–0·04)
0·15 (0·15–0·16)
0·03 (0·03–0·03)
0·03 (0·02–0·03)
0·08 (0·07–0·09)
0·06 (0·04–0·08)
0·09 (0·08–0·10)
0·13 (0·13–0·14)
0·24 (0·18–0·30)
0·04 (0·02–0·08)
0·12 (0·08–0·16)
0·08 (0·06–0·09)
Weight
 
 4·70
 4·45
 4·69
 4·70
 4·68
 4·70
 4·70
 4·70
 4·68
 4·68
 4·69
 4·31
 55·68
 
 4·70
 4·70
 4·65
 4·71
 4·69
 4·64
 28·09
 
 4·61
 4·65
 2·82
 4·15
 16·23
 
100·00
0–0·3 0·3
Figure 4: Meta-analysis for possible severe bacterial infection incidence, by region
*As per random eﬀ ects analysis.
South Asia Sub-Saharan Africa Latin America Overall
Livebirths ≥32 weeks (n)35
Total 46 000 000 34 100 000 10 800 000 91 000 000
Boys 23 700 000 17 400 000 5 500 000 47 000 000
Girls 22 300 000 16 700 000 5 300 000 44 000 000
Studies (n)
Study sites 12 6 4 22
Study population 169 431 80 752 9761 259 944
pSBI cases 15 027 3989 1180 20 196
pSBI incidence risk (95% CI)
Total 0·072 (0·050–0·093) 0·062 (0·041–0·083) 0·117 (0·076–0·159) 0·076 (0·061–0·092)
Boys 0·085 (0.061–0·108) 0·069 (0·042–0·095) 0·149 (0·103–0·195) 0·089 (0·071–0·108)
Girls 0·076 (0·055–0·097) 0·064 (0·038–0·090) 0·118 (0·076–0·160) 0·077 (0·062–0.096)
pSBI case fatality risk (95% CI)
Total 0·087 (0·056–0·118) 0·141 (0·072–0·210) 0·094 (0·063–0·125) 0·098 (0·074–0·122)
Boys 0·093 (0·059–0·128) 0·137 (0·061–0·213) 0·111 (0·086–0·136) 0·103 (0·075–0·130)
Girls 0·076 (0·047–0·104) 0·152 (0·061–0·242) 0·078 (0·033–0·122) 0·090 (0·065–0·114)
pBSI=possible severe bacterial infection.
 Table 2: Summary pooled incidence risk estimates from meta-analyses, by region
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speciﬁ c incidences for pSBI to livebirths by region because 
of the scarcity of data available for each region and the high 
heterogeneity between studies from the same region.
We estimated 6·9 million cases (uncertainty range 
5·5–8·3) of pSBI in neonates among livebirths of 
32 weeks gestation or more (or ≥1500 g birthweight) in 
2012 (table 3).
Discussion
Our estimate of 6·9 million cases (uncertainty range 
5·5 million–8·3 million) of pSBI in south Asia, 
sub-Saharan Africa, and Latin America, suggests that 
both the size of the need-to-treat population and the 
burden of pSBI on health-care systems is substantial. To 
the best of our knowledge, these are the ﬁ rst estimates 
of neonatal pSBI cases, and due to the absence of 
comparable data in resource-rich regions, we have not 
been able to make global estimates; pSBI incidence 
risks and case-fatality risks probably diﬀ er. Because we 
know of no other ﬁ rst estimates of pSBI cases, we do 
not have other estimates for comparison. From these 
estimates we could, however, estimate associated 
deaths. Our mortality estimate of 680 000 neonatal 
deaths was based on only 22 studies, but is consistent 
with estimates of neonatal deaths due to infection from 
the Child Health Epidemiology Reference Group 
(CHERG), which estimated 640 000 worldwide in 2012,11 
and Institute for Health Metrics Evaluation (IHME), 
which estimated 750 000 in 2010.49 The CHERG and 
IHME estimates are based on large datasets (more than 
a million deaths) drawn from vital registration and 
verbal autopsy studies, which report multicause 
mortality and are a more robust approach to 
cause-speciﬁ c mortality estimates. That our estimates 
align closely with these lends support to the accuracy of 
our ﬁ ndings.
For the 6·9 million neonates with pSBI needing 
treatment in sub-Saharan Africa, south Asia, and South 
America, there are scarce data for how many were treated 
in health facilities, and for how many obtained antibiotics 
from commercial providers.50 A review of care seeking for 
neonatal illness in low-income and middle-income 
countries reported that a median of only 59% 
(range 10–100) of parents or guardians seek care for sick 
neonates, with most of the studies (17 [77%] of 22 studies) 
from Asia.51 In some societies, sick neonates, or indeed 
women who have recently given birth, are not given care,52 
or care seeking is delayed, and a neonate with sepsis or 
meningitis might be dead within hours. Our analysis did 
not account for diﬀ ering sociocultural behaviours, such as 
care seeking. However, the eﬀ ect of such a diﬀ erence was 
probably minimal because cases were identiﬁ ed for all but 
one study with active follow-up. We saw increased risk of 
infection and mortality in boys compared with girls, which 
is consistent with increased biological susceptibility in 
boys, as reported in resource-rich regions and in a study of 
acute lower respiratory tract infections.8,53,54 In south Asia, 
previously recorded higher female neonatal mortality has 
been attributed to reduced care seeking by families with 
female neonates who are sick,55–57 which might reverse the 
survival advantage for female neonates.
Our pooled data suggest that sub-Saharan Africa and 
south Asia have a similar incidence risk of pSBI 
(6·2% vs 7·2%), but that the case-fatality risk might be 
25
20
15
10
5
0
0 10 20 30 40
In
cid
en
ce
 ri
sk
 (%
) 
Prospective
Retrospective
Nagpur, India
Belgaum, India
Chongwe and
Kafue, Zambia
Case-fatality risk (%)
South Asia Sub-Saharan Africa Latin America Total*
pSBI cases
Total in millions 3·5 (2·8–4·2) 2·6 (2·1–3·1) 0·8 (0·7–1·0) 6·9 (5·5–8·3)
Male cases in millions† 1·9 (1·5–2·4) 1·4 (1·1–1·8) 0·4 (0·4–0·6) 3·7 (3·0–4·7)
Female cases in millions† 1·6 (1·2–2·0) 1·2 (0·9–1·5) 0·4 (0·3–0·5) 3·2 (2·5–3·9)
pSBI deaths
Total 340 000 (230 000–470 000) 250 000 (170 000–340 000) 00 000 (50 000–110 000) 680 000 (460 000–920 000)
Male cases‡ 190 000 (130 000–260 000) 140 000 (90 000–190 000) 40 000 (30 000–50 000) 370 000 (280 000–460 000)
Female cases‡ 160 000 (110 000–210 000) 120 000 (80 000–160 000) 40 000 (30 000–50 000) 310 000 (220 000–360 000)
Data are cases (uncertainty range). pBSI=possible severe bacterial infection. *Totals for all regions are based on unrounded estimates of regional cases. †Male and female pSBI 
cases calculated from pSBI incidence risk (table 2) adjusted for sex, assuming that male babies were at a 12% increased risk as per the risk ratio. ‡Male and female deaths 
calculated from sex-speciﬁ c pSBI cases and overall case-fatality risk.
Table 3: Estimates of cases of possible severe bacterial infection by region and sex
Figure 5: Scatter plot of risk of possible severe bacterial infection and case 
fatality risk, indicating method of case identiﬁ cation
Outliers with a high case-fatality risk are labelled. 
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higher in sub-Saharan Africa (14·1% vs 8·7%). This ﬁ nding 
could be due to chance, or due to variations in study 
design. However, there might also be real diﬀ erences in 
access to and quality of care, and in risk factors such as 
preterm birth (higher in sub-Saharan Africa) or being 
small for gestational age (higher in south Asia),2,58 or 
maternal infections such as HIV.59 More epidemiological 
data for pSBI and more consistency in diagnostic 
algorithms and case ascertainment in high-burden regions 
are needed to examine and understand any regional 
diﬀ erences in pSBI incidence and case-fatality risk.
An important knowledge gap exists regarding the causes 
of severe neonatal bacterial infection in resource-poor 
settings. Pathogens such as Streptococcus agalactiae 
(group B streptococcus) and Escherichia coli are increasingly 
recognised as important in early onset sepsis in both 
resource-poor and resource-rich settings,60,61 in addition to 
Klebsiella pneumoniae and Staphylococcus aureus.62 
Important diﬀ erences between settings include a probably 
higher incidence of coagulase negative staphylococcal 
infections in resource-rich regions in preterm neonates in 
hospital.62 Preterm neonates are more susceptible to 
infections,63,64 and in resource-rich settings commonly have 
indwelling devices such as neonatal long lines, with which 
these infections are associated. Although extended 
admission to hospital increases exposure of neonates to 
hospital-acquired infection in resource-rich settings, 
hospital-acquired infections are also an increasing problem 
in resource-poor settings,65,66 where anti-sepsis measures 
can be limited by resources and infrastructure. There is 
increasing evidence of antibiotic resistance,65 and more 
data for the pathogens and their susceptibilities are 
essential in understanding whether WHO treatment 
regimens are eﬀ ective.67 Improvement of routine 
assessment and reporting of clinical case failures, as done 
for other diseases,68 could also inform assessment of the 
eﬀ ectiveness of WHO guidelines. This is especially 
important in the context of ongoing research studies, 
which include testing strategies to simplify antibiotic 
treatment regimens and give treatments closer to a 
patient’s home with administration by community health 
workers.69 Other strategies to reduce the burden of 
neonatal morbidity and mortality are diverse;70 those 
associated with reducing severe bacterial infection include 
improvement of sup portive care through simple 
interventions such as kangaroo mother care.71,72 However 
the best strategy is to prevent neonatal infection, which 
includes the develop ment of maternal vaccinations,73 
building on successful maternal vaccination programmes 
such as that for tetanus immunisation,74,75 and improving 
hygiene. Clean delivery and chlorhexidine cord-cleansing 
at and after delivery have been shown to reduce neonatal 
mortality in randomised controlled trials in Pakistan, 
Nepal, and Bangladesh.41,76,77
Our study has important limitations, such as the scarcity 
of input data, with restricted data even within the three 
regions included (ﬁ gure 3). We were unable to standardise 
for method of case ﬁ nding; prospective case ﬁ nding might 
identify cases with a lower case-fatality risk, compared 
with retrospective case ﬁ nding (ﬁ gure 5), probably due to 
reporting bias. Findings from a randomised controlled 
trial in Bangladesh, showed that neonatal pSBI diagnoses 
coincided with scheduled visits by community health-care 
workers.24 However, ﬁ ndings from this trial also showed 
that improved case ﬁ nding through postnatal visits 
(together with antenatal care) reduced neonatal mortality 
by 39%.24 Visits were especially important at times of high 
risk (ie, the ﬁ rst 48 h of life).78 To what extent active 
prospective case ﬁ nding leads to overdiagnosis of well 
neonates, or leads to earlier treatment, is unclear because 
both would reduce case-fatality risk.
We attempted to account for varied study diagnostic 
algorithms by reanalysis according to YICSS criteria 
when possible, but the speciﬁ city of diagnoses might be 
lower than reported in the YICSS study. In studies with 
prospective follow-up, the YICSS algorithm was used for 
screening in home-based surveillance by community 
health workers. However, in the YICSS study, the infants 
were mainly referred by their parents or guardians, and 
the studies were based in outpatient departments of 
large hospitals.12 If the speciﬁ city of the diagnostic 
algorithm was lower in the community than in YICSS, 
because the prevalence of pSBI in the community was 
low, the positive predictive value will be less than 50%, 
perhaps only 25%. Fast breathing, deﬁ ned as a 
respiratory rate greater than 60 breaths per min in 
neonates, seems to have low speciﬁ city as a single sign.79 
The presence of clinical signs might also depend on 
environmental determinants in the community; ﬁ ndings 
from a study in Nepal showed that 49% of all neonates 
had moderate hypothermia (32·0–36·0°C).80 Further 
research is needed to assess optimal diagnostic criteria 
for community screening of pSBI.
The high burden of pSBI in these three regions 
reinforces the urgent need for more investment, action, 
and innovation at all levels.81,82 Improvement of 
prevention, minimisation of delays in recognition of 
illness, and instigation of rapid, appropriate management 
of pSBI is essential to reduce neonatal deaths and long-
term disability. These actions are an important 
component of The Every Newborn Action Plan.11 
Reducing mortality is rightly the main focus for action, 
even in the post-2015 era in view of the large number of 
preventable neonatal deaths. Treatment and innovation 
have been essential in reducing the HIV/AIDS burden, 
and now is the time to also invest in treatment and 
innovation for neonatal care.
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